Skip to content
Precision for Medicine
Contact Us
Oncology CRO_Hero Image_V2 Oncology CRO_Hero Image_V2

Oncology CRO Services

Integrated trials, labs, data, regulatory and biomarker expertise
Award-winning oncology CRO delivering science-led strategies to help you design smarter trials and reach milestones faster

Precision for Medicine is a specialist oncology CRO built for next-generation clinical research. Our integrated ecosystem combines operational excellence with agile workflows, deep biomarker and lab expertise, and regulatory leadership from former FDA experts. With 60% of our team bringing more than eight years of oncology experience, we provide the capabilities you need to manage complexity, accelerate development, and confidently achieve your next milestone.

70
of Precision trials are in Oncology
600
Oncology clinical trials
7
oncology approvals in the last 3 years

Your Partner for Faster, Smarter Oncology Drug Development

Get the clarity and confidence to move your oncology program forward. Precision for Medicine has the scientific depth and operational strength help you make critical decisions, keep timelines on track, and reach milestones that matter. With decades of oncology experience and integrated capabilities, we anticipate challenges before they impact your progress—so you can accelerate development and deliver breakthroughs.

Connect with our Oncology Experts

Comprehensive Support Across Every Stage of Your Oncology Program

Streamline your journey from discovery through development with the only oncology CRO purpose-built for precision.

With 68% of programs in solid tumors and 32% in hematological malignancies, our deep oncology focus translates into faster, more confident decision-making across preclinical and clinical stages, accelerating your path to meaningful outcomes.

Request a proposal

  • Trial Phases & Designs

    Trial Phases & Designs

    End-to-end Oncology Development Support

    • Preclinical development
    • Pre-IND and IND submission support
    • First-in-human/ Phase 1 expertise
    • Early-phase adaptive, basket & umbrella trials
    • Pivotal Phase 2/3 trials
    • Rescue/Transition trials
    • NDA submission support
    • Post-approval trials

  • Indications

    Indications

    Solid tumors, hematological malignancies and rare cancers

    • Breast cancer
    • Lung cancer (NSCLC/SCLC)
    • Gastrointestinal cancers
    • Genitourinary cancers
    • Gynecological cancers
    • Neuroendocrine tumors
    • Sarcomas
    • Rare solid tumors
    • Hematologic malignancies

  • Modalities and Drug Classes

    Modalities and Drug Classes

    Specialized capabilities in advanced therapies

    • Antibody drug conjugates (ADCs)
    • Immuno-oncology (Checkpoint inhibitors and cytokines)
    • Targeted therapies
    • Cell & Gene therapies
    • Radiopharmaceuticals
    • Combination therapies
    • Vaccines

Integrating Oncology Expertise Across Translational, Clinical, and Regulatory Solutions

Deliver oncology therapies at scale with a CRO purpose-built to simplify development for next-generation treatments. From First-Patient-In to first patient impact, our world-class teams and proprietary technologies guide every step of your trial. Overcome complexity, accelerate timelines, and realize your program’s full potential with Precision.

  • Explore
    www.precisionformedicine.comhubfsStreamlining Radiopharmaceutical Clinical Trials Precision Case Study (2)
    clinical-trial-services

    Global CRO Solutions

    Global trials for oncology, rare diseases, and other complex conditions demand expertise. Precision partners with you to overcome challenges through our extensive global footprint, delivering trials that stay on track and on time.
    Explore
    clinical-trial-services

    Global CRO Solutions

    Global trials for oncology, rare diseases, and other complex conditions demand expertise. Precision partners with you to overcome challenges through our extensive global footprint, delivering trials that stay on track and on time.
    Explore
  • Explore
    Regulatory consulting
    regulatory_solutions

    Regulatory Consulting

    Our ex-FDA and regulatory experts ensure compliant submissions, expedited approvals, and seamless agency interactions. From IND to NDA, we accelerate oncology programs while safeguarding data integrity and patient safety.

    Explore
    regulatory_solutions

    Regulatory Consulting

    Our ex-FDA and regulatory experts ensure compliant submissions, expedited approvals, and seamless agency interactions. From IND to NDA, we accelerate oncology programs while safeguarding data integrity and patient safety.

    Explore
  • Explore
    specialty Labs
    specialty-lab-services

    Central & Specialty Lab Services

    Purpose-built to support biomarker-driven development, our labs deliver advanced assay capabilities that power precision oncology and enable smarter, faster decisions.
    Explore
    specialty-lab-services

    Central & Specialty Lab Services

    Purpose-built to support biomarker-driven development, our labs deliver advanced assay capabilities that power precision oncology and enable smarter, faster decisions.
    Explore
  • Explore
    Biospecimen therapeutic areas hero
    biospecimens

    Biospecimen Collections

    Access one of the most comprehensive resources for biospecimens and biomarker services, fueling diagnostic and therapeutic R&D with quality you can trust.
    Explore
    biospecimens

    Biospecimen Collections

    Access one of the most comprehensive resources for biospecimens and biomarker services, fueling diagnostic and therapeutic R&D with quality you can trust.
    Explore
  • Explore
    Key Strategies for Future-Proofing Gene Therapy Assay Validation 2
    genomics_analysis

    Companion Diagnostics

    Bringing tests and therapies to market together requires precision planning. We guide your companion diagnostic strategy to ensure timely commercialization and optimal patient access.
    Explore
    genomics_analysis

    Companion Diagnostics

    Bringing tests and therapies to market together requires precision planning. We guide your companion diagnostic strategy to ensure timely commercialization and optimal patient access.
    Explore
  • Explore
    shutterstock_1091148068
    Virtual-Sample-Management

    Virtual Sample Management

    Lost samples mean lost insights and costly delays. Our virtual sample management solution keeps your data secure, accessible, and actionable, so progress never stalls.
    Explore
    Virtual-Sample-Management

    Virtual Sample Management

    Lost samples mean lost insights and costly delays. Our virtual sample management solution keeps your data secure, accessible, and actionable, so progress never stalls.
    Explore

Oncology CRO Services Powered By Operational Excellence, Scientific Depth & a Focus on Precision

Oncology CRO experience: Clinical Phase – Phase II 32%, Phase I 23%, Phase III 23%, Phase I/II 18%, Other 4%; Cancer Type – Solid Tumor 64%, Hematologic 36%. Clinical Phase Cancer Type Active Project Dashboard Speak with an expert in hematologic or solid tumor trials
Diagram comparing Next-Gen Basket and Umbrella Trials. Basket Trial: Investigational Drug → Tumor Types A, B, C → Expansions: Type A (NO GO), Type B (GO), Type C (GO). Umbrella Trial: Tumor Type X → Markers A, B, N → Expansions: Marker A (GO), Marker B (GO), Marker N (NO GO).

Experts in basket & umbrella trials for oncology early phase development

As an oncology CRO, we specialize in adaptive designs, master protocols, and biomarker-driven strategies that keep your program on track. From basket to umbrella trials, our experts anticipate challenges and optimize trial design to accelerate development and deliver meaningful results.

Explore Clinical Trial Design Services
Global scale

Accelerate Site & Patient Access with the Curated Precision Site Network

Selecting the right sites can make or break your trial. The Precision Site Network (PSN) is a curated group of 100+ pre-vetted oncology sites and investigators across the US, Europe, and Asia, designed to accelerate start-up and improve access to diverse patient populations.

With streamlined agreements and proven relationships, PSN removes barriers that slow trials, so you can focus on advancing therapies that matter.

Explore the Precision Site Network >

100

Global Oncology Centers

Preidentified and prequalified sites give you the advantage of a robust infrastructure, deep therapeutic expertise, and the patient populations critical to your trial’s success.

Precision for Medicine is the winner of the 2025 Fierce Biotech CRO Award for Innovative Solutions in Drug Development

Winner of the 2025 Fierce Biotech CRO Award for Innovative Solutions in Drug Development

Honored for delivering results when it mattered most.

Precision rescued a high-risk hematology-oncology trial through a comprehensive operational and data gap analysis, rebuilding sponsor alignment with proactive collaboration, implementing centralized patient-level data monitoring, and creating custom tracking systems to accelerate regulatory and start-up activities.

Read more

Biomarker Expertise to Power Precision Oncology Trials

We combine advanced technologies and proprietary methods to develop and validate biomarker assays that deliver reliable, actionable data. From nucleic acids to tissue, our oncology specialty labs provide the depth and precision needed to accelerate biomarker-driven development.

Explore Specialty Lab Services >
Oncology Specialty Lab Services

Proprietary Technologies Empowering Precision’s Oncology CRO Services

Scientific innovation is at the core of our approach. We combine advanced methodologies with proprietary platforms to solve complex oncology and immuno-oncology research challenges, delivering deeper insights and faster progress for your trials.
  • Advance Immune Cell Phenotyping
  • Investigate Circulating Tumor Cells (CTCs)
  • Revolutionize Biomarker Operations
  • Smarter Trial Oversight with RBQM

  • Epiontis ID®

    A patented, flexible, and cost-effective platform for immune cell phenotyping based on epigenetic cell counting. With minimal sample processing and simplified global logistics, Epiontis ID delivers robust, reproducible results that can be compared across sites and studies. Ideal for immune monitoring in both early-stage and late-stage clinical trials.
    Explore
    17c6daf230914588bc3d28a14f5beeaf

  • ApoStream®

    ApoStream is an antibody-free technology for capturing and enriching circulating tumor cells (CTCs) and other rare cell types from liquid biopsies. By isolating CTCs from blood, researchers gain a more accessible and less invasive source of information about the primary cancer compared to surgical biopsies, enabling real-time insights that can guide treatment decisions and accelerate development.
    Explore
    iStock-1373474629 (1)

  • virtual Sample Inventory Management (vSIM)

    Oncology trials generate vast amounts of biological samples and associated data. The QuartzBio® vSIM solution centralizes and harmonizes sample data and metadata from all sources—central labs, specialty labs, biorepositories, and EDC systems—into one unified platform. This visibility streamlines operations, reduces risk, and ensures every sample is accounted for, accelerating trial timelines and improving data integrity.
    Explore
    clinical-data-management_card-thumbnail

  • Clinscope™

    Clinscope unifies EDC, CTMS, lab, and other study-specific data streams into a single platform for near real-time oversight powered by expert interpretation. By analyzing complex disease trends, lab results, and safety narratives, our team uses data intelligence to identify efficacy–toxicity trade-offs early, transforming insights into action before risks threaten trial success.
    Explore
    17c6daf230914588bc3d28a14f5beeaf

Behind the breakthroughs: Case studies from complex oncology trials

  • Read Case Study

    Case Study - ONCOLOGY

    Rescue of a Global Phase 3 Trial in Multiple Myeloma

    A global Phase 3 trial in relapsed multiple myeloma faced operational and data quality risks during expansion. Read the full case study to explore how Precision teams not only stabilized the study but also met complete enrollment one month ahead of target while preserving primary endpoint integrity. 
    • 150+
      sites
    • 20+
      countries
    Read Case Study
  • Read Case Study

    Case Study - ONCOLOGY

    Precision’s Path to Zero Data Issues

    This global, first-in-human Phase 1–2 trial evaluated a novel ROS1 inhibitor in patients with NSCLC and other advanced ROS1-positive solid tumors. With a target enrollment of 360 patients, discover how Precision for Medicine delivered an interim data cut with zero unresolved queries, missing pages and SAE reconciliation issues. 
    • 60+
      sites
    • 14+
      countries
    Read Case Study

Curated Insights

Experiences, tips, and perspectives from experts on the front lines of research. 

 All Resources

Recent Oncology articles

Visit blog
Read: Phase 2-3 SCLC Case Study: Strategic Site Selection Drove Recruitment Phase 2-3 SCLC Case Study: Strategic Site Selection Drove Recruitment

Oncology

Phase 2-3 SCLC Case Study: Strategic Site Selection Drove Recruitment

|
    has not third author: true, (SizeLimitingPyMap: {main={hs_id=164725548848, hs_child_table_id=0, hs_updated_at=1754641451547, hs_published_at=1765824414256, description=Alexis Hobbins-White is an accomplished leader who plays a pivotal role in navigating the complex landscape of global oncology and rare disease-focused clinical trials. With a career spanning over 15 years in the clinical trials industry, Alexis brings a wealth of experience across multiple therapeutic areas, showcasing her proficiency in diverse aspects of operational strategy. She specializes in early phase adaptive studies, particularly in immuno-oncology and advanced therapeutics. She has an MSc in Neuroscience and an MA in Biotechnology Law and Ethics., avatar=Image{width=287,height=287,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/PfMxMarkentive/authors/Alexis-Hobbins.png',altText='Alexis-Hobbins',fileId=194096322982}, linkedin=https://www.linkedin.com/in/alexis-hobbins-white-400a1720/, lastname=Hobbins-White, hs_initial_published_at=1713362276020, hs_created_by_user_id=5166971, hs_created_at=1713361952861, hs_is_edited=false, hs_deleted_at=0, name=Alexis, job=Senior Director, Operational Strategy , slug=alexis-hobbins-white, hs_updated_by_user_id=26433386}, second={}, third={}})
  • Alexis Hobbins-White avatar

    Alexis Hobbins-White
Discover
Read: Back to the Source: A Translational Leader on Extending the Living Legacy of Genomic Data Back to the Source: A Translational Leader on Extending the Living Legacy of Genomic Data

Translational Research - Biospecimens - Oncology

Back to the Source: A Translational Leader on Extending the Living Legacy of Genomic Data

|
    has not third author: true, (SizeLimitingPyMap: {main={hs_id=159488778886, hs_child_table_id=0, hs_updated_at=1763657611624, hs_published_at=1765824414256, description=Robert Snyder, PhD, is a seasoned expert with a 20-year track record in genomics, specializing in in vitro diagnostic assay development and bioinformatics. Committed to advancing medical science, he is proficient in regulatory V&V study designs and understands the nuances of orthogonal methods. A collaborative partner in biomedical development, Dr. Snyder champions the critical transition of biospecimens from benchtop to bedside., avatar=Image{width=576,height=576,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/Headshots/Headshots%20no%20background/Robert%20Snyder.webp',altText='Robert Snyder',fileId=165892444501}, linkedin=https://www.linkedin.com/in/robert-snyder-ph-d-9b67b035, hs_name=, hs_path=, lastname=Snyder, PhD, hs_created_at=1709645745117, hs_is_edited=false, hs_deleted_at=0, name=Robert, job=, slug=robert-snyder, email=, hs_updated_by_user_id=26433386}, second={hs_id=164691024166, hs_child_table_id=0, hs_updated_at=1716326265678, hs_published_at=1765824414256, description=Respected veteran of the biospecimen and biomarker laboratory services industry. Honed his expertise through leadership roles in organizations including Roche, Cancer Genetics, and BioServe. Holds a Master of Public Health and a Masters of Business Administration from the Johns Hopkins University., avatar=Image{width=576,height=576,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/Headshots/Headshots%20no%20background/Rob%20Fannon%20Headshot.webp',altText='Rob Fannon Headshot',fileId=165893006477}, linkedin=https://www.linkedin.com/in/rob-fannon-901378/, team=[{id=163072475009, name='Translational Sciences Leadership'}], lastname=Fannon, MPH, MBA, hs_initial_published_at=1713346931329, hs_created_by_user_id=62155952, hs_created_at=1713345787919, hs_is_edited=false, hs_deleted_at=0, name=Rob, job=General Manager, Biospecimen Solutions, slug=rob-fannon, hs_updated_by_user_id=26433386}, third={}})
  • Robert S. avatar

    Robert S.
  • Rob F. avatar

    Rob F.
Discover
Read: Case Study: Biomarker-Driven Enrollment Using Notch Mutation Targeting Case Study: Biomarker-Driven Enrollment Using Notch Mutation Targeting

Clinical Trials - Oncology

Case Study: Biomarker-Driven Enrollment Using Notch Mutation Targeting

|
    has not third author: true, (SizeLimitingPyMap: {main={hs_id=164725548848, hs_child_table_id=0, hs_updated_at=1754641451547, hs_published_at=1765824414256, description=Alexis Hobbins-White is an accomplished leader who plays a pivotal role in navigating the complex landscape of global oncology and rare disease-focused clinical trials. With a career spanning over 15 years in the clinical trials industry, Alexis brings a wealth of experience across multiple therapeutic areas, showcasing her proficiency in diverse aspects of operational strategy. She specializes in early phase adaptive studies, particularly in immuno-oncology and advanced therapeutics. She has an MSc in Neuroscience and an MA in Biotechnology Law and Ethics., avatar=Image{width=287,height=287,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/PfMxMarkentive/authors/Alexis-Hobbins.png',altText='Alexis-Hobbins',fileId=194096322982}, linkedin=https://www.linkedin.com/in/alexis-hobbins-white-400a1720/, lastname=Hobbins-White, hs_initial_published_at=1713362276020, hs_created_by_user_id=5166971, hs_created_at=1713361952861, hs_is_edited=false, hs_deleted_at=0, name=Alexis, job=Senior Director, Operational Strategy , slug=alexis-hobbins-white, hs_updated_by_user_id=26433386}, second={}, third={}})
  • Alexis Hobbins-White avatar

    Alexis Hobbins-White
Discover

Frequently Asked Questions

How is Precision different from other oncology CROs?

Precision for Medicine is purpose-built for biomarker-driven oncology development. We combine global clinical operations with specialty labs, biospecimen sciences, CDx development, and proprietary technologies such as vSIM™ virtual sample management, Epiontis ID®, and ApoStream®.

Our oncology programs are led by senior therapeutic experts, many with 20+ years of oncology experience, ensuring scientific, operational, and regulatory strategy are aligned from first patient in to regulatory submission.

Can you support complex trial designs like basket and umbrella trials?

Yes. Precision has deep expertise in basket, umbrella, platform, and adaptive oncology trial designs.

Our clinical strategists, biostatisticians, and translational scientists work together to:

  • Model dose-finding and expansion strategies
  • Define cohorts and align with emerging regulatory requirements
  • Support regulatory interactions for complex designs
  • Monitor critical patient safety signals early with centralized monitoring
We have experience with executing complex oncology trials with varied endpoints and operational needs, supported by real-time data visibility, central statistical oversight, and integrated biomarker workflows.

How do you accelerate enrollment in competitive oncology indications?

Patients enroll faster through a combination of data-driven feasibility, strong investigator relationships, and our Precision Site Network (PSN), which spans 100+ high-performing oncology centers globally.

We accelerate enrollment using:

  • Pre-qualified oncology sites with proven start-up speed
  • 26% faster IRB/EC approval and 12% faster FPI at PSN sites
  • Sophisticated feasibility models integrating epidemiology, historical performance, and biomarker prevalence
  • Centralized monitoring to remove bottlenecks early
  • Patient-centric protocols supported by ePRO, and DCT capabilities
This allows sponsors to reach target enrollment even in highly competitive tumor types like NSCLC, breast cancer, GI cancers, and multiple myeloma.

What oncology modalities do you have the most experience with?

Precision supports a broad range of oncology modalities, with deep experience in targeted therapies, immuno-oncology, cell and gene therapy, antibody-drug conjugates (ADCs), radiopharmaceuticals, bispecific antibodies, and combination regimens.

How do you handle biomarker strategy and assay validation?

Precision integrates biomarker strategy into the core of trial design. We align clinical, regulatory, and translational teams early to define the right biomarkers, assays, sample plans, and data workflows for each program. Our global specialty labs develop and validate assays including IHC, mIF, flow cytometry, genomic and proteomic methods, under GLP/GCLP conditions, with platforms and controls selected to meet regulatory expectations.

Biomarker data is harmonized with clinical data in real time, enabling confident patient stratification, endpoint assessment, and decision-making throughout the study.

Can Precision take over ongoing or at-risk oncology studies (rescue)?

Yes. Precision is frequently engaged to rescue/transition Phase I–III oncology programs.

Our rescue approach includes:

  • Rapid assessment of data integrity, site performance, and operational bottlenecks
  • Corrective action planning with clear prioritization
  • Re-engagement of underperforming sites and replacement with PSN oncology centers
  • Centralized monitoring to close outstanding queries and restore data reliability
  • Stabilized study governance with sponsor visibility

We have successfully rescued trials in multiple myeloma, solid tumors, NSCLC, and hematologic malignancies, restoring timelines and returning programs to submission-readiness.

Specialized capabilities in every stage of clinical development

Leverage an integrated infrastructure that reduces the inefficiencies inherent in complex development. Integrate lab and trial execution to accelerate speed to market. Precision can customize and converge our capabilities to meet your program's unique needs—driving efficiency, agility, and success from start to finish.

  • Global CRO services Discover Explore
    Global Clinical Trial Services

    Global CRO
    Services

    Award-winning CRO with deep oncology and rare disease expertise

    Explore
  • Global Central and Specialty Lab Services Discover Explore
    specialty-lab-services

    Global Laboratory
    Services

    Exceptional translational and biomarker sciences with global central lab services

    Explore
Loading...